Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure
Why the study?
Does omecamtiv mecarbil reduce a composite of a heart-failure event or death from cardiovascular causes in patients with heart failure and a reduced ejection?
Population
Patients with heart failure and a reduced ejection
Comparison
Omecamtiv mecarbil vs placebo
Authors
Discussion
Loading...
Member takes
Implication
Supports omecamtiv mecarbil in HFrEF management; extends evidence for myosin activation on clinical outcomes.
Structured PICO
Does omecamtiv mecarbil reduce a composite of a heart-failure event or death from cardiovascular causes in patients with heart failure and a reduced ejection?
P
Population
Patients with heart failure and a reduced ejection
I
Intervention
Omecamtiv mecarbil
C
Comparator
Placebo
O
Outcome
Composite of a heart-failure event or death from cardiovascular causescomposite
Omecamtiv mecarbil lowers the incidence of heart failure events or cardiovascular death in patients with systolic heart failure.
Cite This Study
Teerlink et al. (2020) studied this question.